Recent Patents and Advances on Nanotechnologies against Coronavirus

Author(s):  
Roozbeh Abedini-Nassab ◽  
Naeemeh Mahdaviyan

: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one of the seven known coronaviruses infecting humans; HKU1, 229E, NL63, OC43, acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2, the last three of which can cause severe symptoms in patients. COVID-19, previously known as 2019 novel coronavirus, caused by SARS-CoV-2, was first reported in Wuhan, China, in late 2019, and quickly resulted in a major epidemic across the world. Although the origin of SARS-CoV-2 is not clear yet, genome sequencing results suggest that this is the third reported spillover of an animal coronavirus to humans, from 2002. The development of detection, therapeutic, and prevention strategies for COVID-19 is a fundamental task towards curing infected people and competing with the pandemic. Because of their similarities, scientists believe that treatment/detection methods similar to what were used against the illnesses caused by SARS-CoV or MERS-CoV may be effective for curing/detecting COVID-19. Here, we review the recent nanotechnology techniques used for treating and testing SARS-CoV, MERS-CoV, and SARS-CoV-2, and potential therapeutic options for curing COVID-19.

2020 ◽  
Vol 12 (2) ◽  
pp. 156-157
Author(s):  
Mohammad Mostafa Ansari Ramandi ◽  
Mohammadreza Baay ◽  
Nasim Naderi

The disaster due to the novel coronavirus disease 2019 (COVID-19) around the world has made investigators enthusiastic about working on different aspects of COVID-19. However, although the pandemic of COVID-19 has not yet ended, it seems that COVID-19 compared to the other coronavirus infections (the Middle East Respiratory Syndrome [MERS] and Severe Acute Respiratory Syndrome [SARS]) is more likely to target the heart. Comparing the previous presentations of the coronavirus family and the recent cardiovascular manifestations of COVID-19 can also help in predicting possible future challenges and taking measures to tackle these issues.


2020 ◽  
Vol 58 (5) ◽  
Author(s):  
Suliman Khan ◽  
Rabeea Siddique ◽  
Muhammad Adnan Shereen ◽  
Ashaq Ali ◽  
Jianbo Liu ◽  
...  

ABSTRACT The new decade of the 21st century (2020) started with the emergence of a novel coronavirus known as SARS-CoV-2 that caused an epidemic of coronavirus disease (COVID-19) in Wuhan, China. It is the third highly pathogenic and transmissible coronavirus after severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in humans. The source of origin, transmission to humans, and mechanisms associated with the pathogenicity of SARS-CoV-2 are not yet clear, however, its resemblance to SARS-CoV and several other bat coronaviruses was recently confirmed through genome sequencing-related studies. The development of therapeutic strategies is necessary in order to prevent further epidemics and cure infections. In this review, we summarize current information about the emergence, origin, diversity, and epidemiology of three pathogenic coronaviruses with a specific focus on the current outbreak in Wuhan, China. Furthermore, we discuss the clinical features and potential therapeutic options that may be effective against SARS-CoV-2.


2020 ◽  
Vol 41 (04) ◽  
pp. 568-578 ◽  
Author(s):  
Jaffar A. Al-Tawfiq ◽  
Ziad A. Memish

AbstractEmerging infectious diseases continue to be of a significant importance worldwide with the potential to cause major outbreaks and global pandemics. In 2002, the world had witnessed the appearance of the severe acute respiratory syndrome coronavirus in China which disappeared abruptly within 6 months. About a decade later, a new and emerging novel coronavirus named the Middle East respiratory syndrome coronavirus (MERS-CoV) was described in a patient from Saudi Arabia. These two coronaviruses shared multiple similarities in the epidemiology, clinical presentations, and posed challenges in its prevention and management. Seven years since its discovery, MERS-CoV continues to be a lethal zoonotic pathogen capable of causing severe pneumonia with high case fatality rates and the ability to cause large health care-associated outbreaks.


2021 ◽  
Vol 16 (11) ◽  
pp. 1934578X2110412
Author(s):  
Hui Liu ◽  
Wenxia Zhu ◽  
Yilin Wu ◽  
Caini Jiang ◽  
Lili Huo ◽  
...  

Before COVID-19, many viruses have infected humans, so what caused COVID-19 to be considered as a pandemic? COVID-19 belongs to the coronavirus family that includes severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS). This family has caused a large number of deaths all over the world. How risky is the novel coronavirus? People and their careers were disrupted, and many businesses all over the world are now closed. From here, it seems to us that this virus is something that can make people feel afraid. In this article, we will try to understand the severity of this virus, and then disclose the available ways to confront it and ways that might improve the ability to face it, either now or in the future. Upon comparing COVID-19 with seasonal flu, we have found that COVID-19 is about 10 times more deadly, although it is not the most infectious virus. In this review, we will discuss how healthy nutrition and lifestyle may help to prevent and treat diseases, and especially COVID-19. We will focus on how to follow healthy nutrition habits and lifestyles to stop the dangers of COVID-19.


2021 ◽  
Vol 27 ◽  
Author(s):  
Avneet Kaur ◽  
Vijay Bhalla ◽  
Mohammed Salahuddin ◽  
Syed Obaidur Rahman ◽  
Faheem Hyder Pottoo

Abstract:: Coronavirus was first discovered during the year 1930 and since then vrious coronaviruses like HKU1, MERS-CoV , NL63 and SARS-CoV-2 had been found to infect humans. The COVID-19 pandemic caused by SARS-CoV-2 is spreading at an alarming rate thereby created health emergency around the world. SARS-CoV2 is reportedly to be originated from wet animal market of Wuhan, China. Since then the world is searching for effective way to manage and treat the COVID-19 infection. The infections has already multiplied with several folds compared to the number of person infected by Middle East Respiratory Syndrome Coronavirus and Severe Acute Respiratory Syndrome. In order to fill the gap of knowledge about this virus, several evidences are required to control it so more lives could be saved. The present review is based on the publicly available literature in order to explore the knowledge regarding epidemiology, virology, diagnosis, clinical features, pharmacological and therapeutic ways to treat the novel coronavirus. This can be helpful in offering novel insights and potential therapeutics in fighting this disease.


2021 ◽  
Author(s):  
Anna Golke ◽  
Karolina Piekarska ◽  
Tomasz Dzieciątkowski

current pandemic caused by novel coronavirus SARS-CoV-2 pandemic has been described as a global health emergency. The outbreak of this virus has raised a number of questions: what exactly is SARS-CoV-2? How transmissible the novel coronavirus is? How severely affected are patients infected with SARS-CoV-2? What are the risk factors for COVID-19? What are the differences between this novel coronavirus and other coronaviruses? To answer these questions, a comparative study of three pathogenic coronaviruses that primarily invade the human respiratory system and may cause death, namely, severe acute respiratory syndrome (SARS-CoV-1), Middle East respiratory syndrome (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Middle East respiratory syndrome coronavirus (MERS-CoV). This review describes the source of origin, transmission, and pathogenicity of these viruses. Prevention of SARS-CoV-2 spreading entails home isolation of suspected cases and those with mild illnesses and strict infection control measures at hospitals that include contact and droplet precautions. The novel coronavirus spreads faster than its two predecessors – the SARS-CoV-1 and MERS-CoV – but has lower fatality rate. The global impact of this new pandemic is still uncertain, but it is a challenge to healthcare systems around the world.


2020 ◽  
Vol 10 (3) ◽  
pp. 251-253
Author(s):  
Tooba Masood

Coronavirus belongs to a large family of viruses that usually cause respiratory illness in human beings that can be mild and severe depending upon the strain. In 2002, the outbreak of SARS (severe acute respiratory syndrome) reported more than 8000 infected cases with 774 mortalities. In 2012, the outbreak of MERS (middle east respiratory syndrome) infected around 2494 people and 858 deaths were reported according to the WHO. In January 2020, a new strain of coronavirus named 2019-nCoV has been identified in China. The number of confirmed cases has been increasing reaching 5,593,631 cases worldwide with 353,334 deaths up till 28th May 2020 according to WHO situation report-129. Concerned authorities are working on minimizing its spread. Prevention guidelines have been released by WHO, hoping to control the transmission and save the world from the effects of this novel virus.


2020 ◽  
Vol 15 (9) ◽  
pp. 625-648
Author(s):  
SK Manirul Haque ◽  
Omar Ashwaq ◽  
Abdulla Sarief ◽  
Abdul Kalam Azad John Mohamed

The coronavirus disease (COVID-19) was first identified in China, December 2019. Since then, it has spread the length and breadth of the world at an unprecedented, alarming rate. Severe acute respiratory syndrome coronavirus (SARS-CoV)-2, which causes COVID-19, has much in common with its closest homologs, SARS-CoV and Middle East respiratory syndrome-CoV. The virus–host interaction of SARS-CoV-2 uses the same receptor, ACE2, which is similar to that of SARS-CoV, which spreads through the respiratory tract. Patients with COVID-19 report symptoms including mild-to-severe fever, cough and fatigue; very few patients report gastrointestinal infections. There are no specific antiviral strategies. A few strong medications are under investigation, so we have to focus on proposals which ought to be taken to forestall this infection in a living host.


2020 ◽  
Vol 35 (1-2) ◽  
Author(s):  
Pradeep Pagaria ◽  
L. R. Choudhary ◽  
Haridayal Choudhary ◽  
Ganga Ram ◽  
Turfan Khan

Coronavirus outbreak was first reported in Wuhan, China on 31 December, 2019. Coronavirus (CoV) is a large family of viruses that causes illness. It ranges from the common cold to more severe diseases like Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). The novel coronavirus is a new strain of virus that has not been identified in human so far.


2020 ◽  
Vol 1 (supplement) ◽  
Author(s):  
Raees Khan ◽  
Shumaila Naz ◽  
Fawad Muhammad ◽  
Syed Babar Jamal ◽  
Sumra Wajid Abbasi ◽  
...  

The death toll and the total number of infected individuals due to the ongoing pandemic of SARS-CoV-2 infection have exceeded that of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) as the disease has raged around the world. So far the global efforts to tackle COVID-19 include the launch of Sputnik V vaccine by Russia, 42 vaccines presently undergoing clinical trials on humans and around 92 vaccines under preclinical active investigation in animals. Majority of the SARS-CoV-2 infected individuals have been reported to show mild symptoms whereas a considerable number show no symptoms at all. SARS-CoV-2 is believed to spread from infected individuals who are asymptomatic in addition to the symptomatic individuals. In this review we discussed how the mildly infected and asymptomatic individuals raise serious concerns and complicate the processes of screening, detection, quarantine, tracking and treatmentthatareinpracticetopreventthetransmissionofthe COVID-19.


Sign in / Sign up

Export Citation Format

Share Document